Skip to Main Content

Camostat mesylate in COVID-19 Outpatients


Diseases of the Respiratory Systems | COVID-19 Outpatient


What is the purpose of this trial?

The rationale of the present clinical trial is that an orally available drug given to outpatients that could reduce the viral burden in the upper respiratory tract could forestall complications of SARS-CoV-2 infection and reduce transmission from one infected individual to another.

  • Trial with
    Yale University School of Medicine
  • Start Date
  • End Date
Trial Image

For more information about this study, contact:

Angela Nunez

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 877.978.8343

  • Last Updated
  • Study HIC